Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
MK-677 (Ibutamoren) vs Sermorelin
An educational, source-based comparison of MK-677 (Ibutamoren) and Sermorelin — how each peptide works, what it's researched for, and what to know before going deeper.
Orally bioavailable non-peptide ghrelin mimetic.
Technically a small-molecule ghrelin receptor agonist (not a peptide), often grouped with peptide GH research. Orally bioavailable, it elevates GH and IGF-1 over 24 hours and increases appetite.
- GH/IGF-1 elevation in adults
- Lean mass and bone density in elderly
- Sleep quality (slow-wave sleep)
- • Not FDA-approved.
- • Insulin resistance and fluid retention reported.
- • Banned by WADA.
A synthetic 29-amino-acid analog representing the active fragment of endogenous GHRH. Stimulates the pituitary to release GH in a physiologic, pulsatile pattern. Previously FDA-approved (Geref) for pediatric GH deficiency diagnosis before discontinuation for commercial reasons.
- Adult GH deficiency
- Pediatric short stature (historical)
- Sleep quality and body composition in aging
- • No longer commercially available as an FDA-approved drug; available via compounding.
- • Requires physician oversight.
- • Banned in competitive sport.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| MK-677 (Ibutamoren) | MK-677 increases GH and IGF-1 in elderly adults | Annals of Internal Medicine | 2008 | Two-year RCT showing sustained IGF-1 elevation and lean mass increase. |
| Sermorelin | Sermorelin in adult growth hormone deficiency | Endocrine Practice | 2010 | Reviewed efficacy on body composition, energy, and sleep markers. |
Side-effect & safety grid
- Not FDA-approved.
- Insulin resistance and fluid retention reported.
- Banned by WADA.
- No longer commercially available as an FDA-approved drug; available via compounding.
- Requires physician oversight.
- Banned in competitive sport.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
MK-677 (Ibutamoren) vs Sermorelin — Key differences
- Class: MK-677 (Ibutamoren) is classified as Growth Hormone Axis · Small Molecule, while Sermorelin is Growth Hormone Axis.
- Primary research focus: MK-677 (Ibutamoren) — gh/igf-1 elevation in adults; Sermorelin — adult gh deficiency.
- Tag: Growth hormone · Oral vs Growth hormone.